MSD concludes Terns acquisition to expand CML pipeline

MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML). The FDA granted breakthrough therapy designation to TERN-701 for adults with Philadelphia chromosome-positive CML without the T315I mutation. Following the tender completion, MSD effected a merger with its subsidiary into Terns. Credit: Sergiy Palamarchuk / Shutterstock.com. Merck & Co (MSD) has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML). Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD. Multiple…

Source: Pharmaceutical Technology